share_log

Star Lake BioscienceZhaoqing Guangdong's (SHSE:600866) Earnings Trajectory Could Turn Positive as the Stock Ascends 5.7% This Past Week

Star Lake BioscienceZhaoqing Guangdong's (SHSE:600866) Earnings Trajectory Could Turn Positive as the Stock Ascends 5.7% This Past Week

廣東星湖生物科技(上海證券交易所股票代碼:600866)的收益軌跡可能轉爲正值,因爲該股上週上漲了5.7%
Simply Wall St ·  02/09 18:36

The simplest way to benefit from a rising market is to buy an index fund. But if you buy individual stocks, you can do both better or worse than that. Unfortunately the Star Lake Bioscience Co., Inc.Zhaoqing Guangdong (SHSE:600866) share price slid 36% over twelve months. That falls noticeably short of the market decline of around 22%. Longer term investors have fared much better, since the share price is up 1.0% in three years. Shareholders have had an even rougher run lately, with the share price down 24% in the last 90 days. But this could be related to the weak market, which is down 13% in the same period.

從市場上漲中獲益的最簡單方法是購買指數基金。但是,如果你買入個股,你的表現可能比這更好或更差。不幸的是,廣東肇慶星湖生物科學有限公司(上海證券交易所代碼:600866)的股價在十二個月內下跌了36%。這明顯低於22%左右的市場跌幅。長期投資者的表現要好得多,因爲股價在三年內上漲了1.0%。股東們最近的表現更加艱難,股價在過去90天中下跌了24%。但這可能與疲軟的市場有關,同期市場下跌了13%。

The recent uptick of 5.7% could be a positive sign of things to come, so let's take a look at historical fundamentals.

最近上漲5.7%可能是即將發生的事情的積極信號,因此讓我們來看看歷史基本面。

There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS).

不可否認,市場有時是有效的,但價格並不總是能反映潛在的業務表現。研究市場情緒如何隨着時間的推移而變化的一種方法是研究公司股價與其每股收益(EPS)之間的相互作用。

Unfortunately Star Lake BioscienceZhaoqing Guangdong reported an EPS drop of 29% for the last year. This proportional reduction in earnings per share isn't far from the 36% decrease in the share price. Given the lower EPS we might have expected investors to lose confidence in the stock, but that doesn't seemed to have happened. Rather, the share price is remains a similar multiple of the EPS, suggesting the outlook remains the same.

不幸的是,廣東肇慶星湖生物科技有限公司報告稱,去年每股收益下降了29%。每股收益的比例下降與股價下跌36%相差不遠。鑑於每股收益較低,我們可能預計投資者會對該股失去信心,但事實似乎並非如此。相反,股價仍然是每股收益的相似倍數,這表明前景保持不變。

You can see how EPS has changed over time in the image below (click on the chart to see the exact values).

您可以在下圖中看到 EPS 隨時間推移的變化(點擊圖表查看確切值)。

earnings-per-share-growth
SHSE:600866 Earnings Per Share Growth February 9th 2024
上海證券交易所:600866 每股收益增長 2024 年 2 月 9 日

Dive deeper into Star Lake BioscienceZhaoqing Guangdong's key metrics by checking this interactive graph of Star Lake BioscienceZhaoqing Guangdong's earnings, revenue and cash flow.

查看這張廣東星湖生物科學的收益、收入和現金流互動圖表,深入了解廣東星湖生物科學的關鍵指標。

A Different Perspective

不同的視角

We regret to report that Star Lake BioscienceZhaoqing Guangdong shareholders are down 36% for the year. Unfortunately, that's worse than the broader market decline of 22%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Longer term investors wouldn't be so upset, since they would have made 3%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. Before forming an opinion on Star Lake BioscienceZhaoqing Guangdong you might want to consider these 3 valuation metrics.

我們遺憾地報告,廣東肇慶星湖生物科技股東今年下跌了36%。不幸的是,這比整個市場22%的跌幅還要嚴重。但是,可能只是股價受到了更廣泛的市場緊張情緒的影響。如果有很好的機會,可能值得關注基本面。長期投資者不會那麼沮喪,因爲他們本可以在五年內每年賺3%。如果基本面數據繼續顯示長期可持續增長,那麼當前的拋售可能是一個值得考慮的機會。在對廣東星湖生物科學發表意見之前,你可能需要考慮這三個估值指標。

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

當然,通過尋找其他地方,你可能會找到一筆不錯的投資。因此,請看一下我們預計收益將增加的這份免費公司名單。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論